Aim. Investigating quality of life, anxiety, aggression and depression disorders in testicular cancer during chemotherapy and after anticancer treatment. Evaluation of correlation between quality of life domains and mental disorders. Method. Participants were 111 men: 57 testicular cancer patients during chemotherapy and 54 survivors at least 6 months after treatment for testicular cancer. The World Health Organization Quality of Life Instrument (WHOQoL-BREF) and the Hospital Anxiety Depression Scale (HADS) were used to study. Results. The assessment of general health was higher in survivors than in patients during chemotherapy. Anxiety and depression disorders were defined by a score >= 8 on the HADS subscales. The prevalence of anxiety disorder was 40% (anxiety syndrome - 15%) in patients during chemotherapy and 18.5% in patients after treatment. The prevalence of depression disorder was 14.6% in patients during chemotherapy and 9.3% in patients after treatment. The prevalence of aggression was 5.6% in patients during chemotherapy and 18.9% in survivors. Anxiety and depression disorders correlated with quality of life and self-health perception, psychological and social domains. Conclusion. Testicular cancer patients during chemotherapy assessed their health lower. Chemotherapy for testicular cancer was associated with higher levels of anxiety and depression. Survivors after testicular cancer therapy have an increased risk of a higheraggression level.